FDA granted permission to doctors at Stanford University Medical Center to transplant immature neural cells into the brains of six children with Batten disease, a degenerative, fatal illness. If approved by an internal Stanford review board, the transplant aims to have the immature cells grow into mature brain cells capable of producing a missing enzyme, a treatment that has shown promise in Batten-afflicted mice. Stem Cells, the biotech firm that developed the treatment, hopes the trial will demonstrate the efficacy and safety of the transplant.

Related Summaries